Skip to main content
padlock icon - secure page this page is secure

Open Access Investigation of antibiotic and antibacterial agent cross-resistance in target bacteria from homes of antibacterial product users and nonusers

Download Article:

You have access to the full text article on a website external to Ingenta Connect.

Please click here to view this article on Wiley Online Library.

You may be required to register and activate access on Wiley Online Library before you can obtain the full text. If you have any queries please visit Wiley Online Library

Abstract e.c. cole, r.m. addison, j.r. rubino, k.e. leese, p.d. dulaney, m.s. newell, j. wilkins, d.j. gaber, t. wineinger and d.a. criger. 2003. Aim:

To describe the relationship between antibiotic and antibacterial resistance in environmental and clinical bacteria from home environments across geographical locations, relative to the use or nonuse of antibacterial products, with a focus on target organisms recognized as potential human pathogens. Methods and Results:

In a randomized study, environmental and clinical samples were collected from the homes of antibacterial product users (n = 30) and nonusers (n = 30) for the isolation of target bacteria for antibiotic and antibacterial testing in three geographical areas (in USA and UK). Isolates were tested for antibiotic susceptibility, with selected antibiotic-resistant and antibiotic-susceptible isolates tested against four common antibacterial agents (triclosan, para-chloro-meta-xylenol, pine oil and quaternary ammonium compound). Prequalified users and nonusers at each location were randomly selected after meeting exclusionary criteria.

Of 1238 isolates, more target bacteria were recovered from nonuser than user homes. Of Staphylococcus aureus isolates (n = 33), none showed resistance to oxacillin or vancomycin; for Enterococcus sp. (n = 149), none were resistant to ampicillin or vancomycin; and for Klebsiella pneumoniae (n = 54)and Escherichia coli (n = 24), none were resistant to third generation cephalosporins. Antibiotic resistance to one or more of the standard test panel drugs for Gram-positive and Gram-negative target bacteria was comparable between nonuser and user homes for both environmental and clinical isolates [e.g. resistance of environmental coagulase-negative (CN) Staphylococcus sp. was 73·8% (124/168) from nonuser homes and 73·0% (111/152) from user homes, and Enterobacteriaceae other than E. coli, 75·9% (186/245) from nonuser homes compared with 78·0% from user homes]. Of 524 Gram-negatives tested against preferred/alternative drugs, 97·1% (509/524) were susceptible to all antibiotics, across both groups. Isolates of S. aureus, Enterococcus sp. and CN Staphylococcus sp. susceptible to all preferred treatment drugs showed comparable antibacterial minimum inhibitory concentration (MIC) results between nonuser and user home isolates. For Gram-positives resistant to one or more preferred drugs, greatest resistance to antibacterial active ingredients was found in the nonuser group. For Gram-negatives, the antibacterial MIC data were comparable for isolates that were fully susceptible and resistant to one or more preferred/alternative treatment antibiotics. Conclusions:

The results showed a lack of antibiotic and antibacterial agent cross-resistance in target bacteria from the homes of antibacterial product users and nonusers, as well as increased prevalence of potential pathogens in nonuser homes. Significance and Impact of the Study:

It refutes widely publicized, yet unsupported, hypotheses that use of antibacterial products facilitates the development of antibiotic resistance in bacteria from the home environment.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: antibacterial; antibiotic; bacteria; clinical; environmental; home; resistance

Document Type: Research Article

Affiliations: 1: DynCorp Health Research Services, Morrisville, NC, USA and 2: Reckitt Benckiser Inc., Montvale, NJ, USA

Publication date: 01 October 2003

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more